To summarize, although IRF-5P68 mutation is present in malignant hematopoietic diseases, ATL and CLL, the link between the novel IRF-5 point mutation to clinical implications, such as pathogenesis, drug resistance and prognosis, remains to be clarified. Here, TRIM63 is linked to B-cell chronic lymphocytic leukemia.